Cytomegalovirus (CMV) in allogeneic hematopoietic stem cell transplant patients

Not Applicable

Completed

• Conditions: Cytomegalovirus infection in transplanted patients; Infections and Infestations

• Registration Number: ISRCTN78128786
• Lead Sponsor: Takeda (United States)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-25
• Study Completion: 2021-12-06
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 379

Inclusion Criteria

Cohort 1: Resistant/refractory/intolerant inclusion criteria:
1. Aged =18 years at the time of the HSCT
2. Received an HSCT after 1 January 2014
3. Diagnosed with CMV infection any time after the HSCT date
4. Characterized as resistant to currently available treatments, OR refractory to currently available treatments, OR considered intolerant to currently available treatments
5. Follow-up data are available for at least 12 months (1 year) after being characterized in item (4) (above) or until death, whichever occurs first

Cohort 2: Pre-emptive treatment for CMV viremia inclusion criteria:
1. Aged =18 years at the time of the HSCT
2. Received an HSCT after 1 January 2017
3. Diagnosed with CMV viremia any time after the HSCT date
4. Received pre-emptive treatment
5. Follow-up data are available for at least 12 months (1 year) after being characterized in item (4) (above) or until death, whichever occurs first

Exclusion Criteria

Positive test for HIV before the HSCT

Study & Design

• Study Type: Observational
• Study Design: Not specified